Funder
Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Fundação de Amparo à Pesquisa do Estado de São Paulo
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Odaka C, Mizuochi T (2000) Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clin Exp Immunol 121:515–522. https://doi.org/10.1046/j.1365-2249.2000.01323.x
2. Ministério da Saúde (2022) Secretaria De Ciência, Tecnologia, Inovação E Insumos Estratégicos em Saúde. Departamento De Assistência Farmacêutica E Insumos Estratégicos. Relação Nacional De Medicamentos Essenciais Rename 2022 [recurso eletrônico]. / Ministério da Saúde, Secretaria de
3. Abdel-Megied AM, Kovalenko S, Elbarbry FA et al (2023) LC–MS/MS bioanalytical method for the quantitative analysis of nifedipine, bisoprolol, and captopril in human plasma: application to pharmacokinetic studies. Biomed Chromatogr 37:1–14. https://doi.org/10.1002/bmc.5664
4. Giudicelli J, Chaignon M, Richer C et al (1984) Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. Br J Clin Pharmacol 18:749–758. https://doi.org/10.1111/j.1365-2125.1984.tb02538.x
5. Orona-Návar C, García-Morales R, Rubio-Govea R et al (2018) Adsorptive removal of emerging pollutants from groundwater by using modified titanate nanotubes. J Environ Chem Eng 6:5332–5340. https://doi.org/10.1016/j.jece.2018.08.010